Biotechs and Providers Weigh in on 340B Medicaid MCO Drug Proposed Rule

by Admin | July 30, 2015 3:22 pm

July 30, 2015—Biopharmaceutical manufacturers and healthcare providers say they appreciate the Centers for Medicare & Medicaid Services’ proposed regulation that would make Medicaid managed care organizations responsible for identifying 340B claims in the Medicaid MCO context. But the two differ about how the requirement should be carried out.

 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2015/07/biotechs-and-providers-weigh-in-on-340b-medicaid-mco-drug-proposed-rule/

---